We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators. Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan. With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development. Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.
We're tracking XtalPi Inc.'s market expansion
New Product & Tech activity — 3 fresh signals just appeared.
How XtalPi Inc.'s international expansion compares to its competitors
XtalPi Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 XtalPi Inc.You | 0 | 0 | — | 0 | 0 |
Head of Brand
View postingShanghai, China · 6d ago
Head of Computational Biology
View postingShanghai, China · 3w ago
AI化学总监
View postingShanghai, China · 3w ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
XtalPi's AI-discovered PRMT5 inhibitor PEP08 begins patient recruitment for solid tumors in Phase I trials. The company launches a second synthetic lethality drug discovery project with PharmaEngine.
muShanghai, a month-long pop-up city by The Mu, launched with 800 selected builders from 2,000 applicants. The program features ClawCon premiere and 90+ events across AI, biotech, robotics, and culture.
XtalPi launched Tensotide™, an innovative oral food ingredient for blood sugar management, receiving US Self-affirmed GRAS certification. Developed via AI platform PepiX™, it reduces postprandial glucose peaks by 30% in animal models.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about XtalPi Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
